art de vany glutathione Frontiers Glutathione Injections Los Angeles &

BPC-157 & TB-500 Specialization: Depth of peptide menu, formulation expertise, and availability of combination blends

doi: 10.3390/antiox11061085 20

Williams A

(2022) demonstrated Cerebrolysin's effects on Alzheimer's disease biomarkers in a randomized controlled trial, providing objective biological evidence for its neurotrophic activity (PMID: 36155516) Regulatory Validation: Approved for clinical use in over 40 countries for indications including stroke, traumatic brain injury, and dementia (though not FDA-approved in the United States) Dihexa: Preclinical Only, with Integrity Concerns Dihexa's evidence base is entirely preclinical and has faced significant scientific integrity challenges: Foundational Research: Wright et al

During a median follow-up of 27.5 months, lobar ICH events (OR 0.10, p = 0.015), presence of cSS (OR 0.19, p = 0.028), high white matter hyperintensities Fazekas score (OR 0.41, p = 0.007) were negatively associated with favorable outcome after adjustment for age, sex and immunosuppressive treatments